Studie
A phase 2 study of Erdafintinib in subjects with advanced Solid Tumors and Selected FGFR Gene Alterations
- Erkrankungsgruppe:
- Solide Tumore
- Organsystem:
- Sonstiges
- Stadium:
- Ersterkrankung
- Standort:
- Essen
- EudraCT:
- 2019-002113-19
- Prüfplan-Code:
- 42756493CAN2002
- Phase:
- II
- Prüfsubstanz:
- Erdafitinib
- Sponsor:
- Jansen - Cilag GmbH